Vineeth Sukrithan

Assistant Professor of Medicine

The Ohio State University Wexner Medical Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Vineeth Sukrithan is an Assistant Professor of Medicine at The Ohio State University Wexner Medical Center in the United States. His research areas focus on neuroendocrine tumors, including their treatment strategies and associated complications, as well as the role of carcinogens in lung cancer development. Dr. Sukrithan has published recent articles addressing various therapeutic approaches and clinical trials in neuroendocrine neoplasms and thyroid cancers.

Articles (13)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Collaborators (4)

Lai Wei

Research Assistant Professor

Ohio State University

UNITED STATES

View details

Jennifer Sipos

Professor

Ohio State University

UNITED STATES

View details

Joseph Locker

Professor

University of Pittsburgh

UNITED STATES

View details

Nancy A Curtis

Ohio State University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Vineeth Sukrithan

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE

Targeting anti-apoptosis as a therapeutic strategy in neuroendocrine neoplasms

Smoking-Associated Carcinogen–Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation

Trans-arterial embolization versus chemoembolization for neuroendocrine liver metastases: a propensity matched analysis

Management of metastatic pheochromocytomas and paragangliomas: when and what

A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

Kinase inhibitors in thyroid cancers

Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib

An Evaluation of Clinical Efficacy of Immune Checkpoint Inhibitors for Patients with Anaplastic Thyroid Carcinoma

Pembrolizumab in a Patient with Treatment-Naïve Unresectable BRAF-Mutation Negative Anaplastic Thyroid Cancer.

Emerging drugs for the treatment of adrenocortical carcinoma.

Targeted Inhibition of the E3 Ligase SCF<sup>Skp2/Cks1</sup> Has Antitumor Activity in <i>RB1</i>-Deficient Human and Mouse Small-Cell Lung Cancer.

Collaborators (4)

Lai Wei

Jennifer Sipos

Joseph Locker

Nancy A Curtis

Make your next move.